Malvern Instruments has acquired NanoSight, the UK-based nanoparticle characterization company.
Malvern Instruments, a provider of instrumentation for materials and biophysical characterization, has acquired nanoparticle characterization company NanoSight. The acquisition was completed on Sept. 27, 2013.
NanoSight has developed and commercialized Nanoparticle Tracking Analysis (NTA). The company’s instrumentation and software enable multi-parameter analysis and characterization of many different types of nanoscale particles. Nanosight’s ability to analyze particle size, concentration, zeta potential, and aggregation, closely aligns with Malvern’s Zetasizer range, extending Malvern’s solutions for those working at the nanoscale.
NanoSight will continue to operate from its current facilities in Amesbury, Wiltshire, UK, under the existing management team.
Source: NanoSight
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.